On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.

The move followed a Dutch patent court ruling that imposed an injunction on Merck's Keytruda SC in multiple EU markets. The court found the subcutaneous version infringed Halozyme Therapeutics' MDASE patent and rejected Merck's validity challenge. The restriction applies to Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The intravenous version of Keytruda remains unaffected. Separately, Merck announced a global license agreement for SPR 2015, a preclinical oral KRAS G12D molecular glue degrader, with a potential total value of $2.13 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)